Send us a text

This episode of the Doc2Doc podcast features Dr. Christopher Riemann of the Cincinnati Eye Institute. Dr. Riemann shares insights into the FIXER Trial, a Phase III study evaluating the use of methotrexate to prevent proliferative vitreoretinopathy (PVR) in retinal detachment surgery.

Listeners will gain a deeper understanding of:
☑️The clinical burden of PVR and its impact on patient outcomes
☑️Methotrexate’s mechanism of action and historical use in ophthalmology
☑️The FIXER Trial’s innovative design and promising interim results
☑️Opportunities for collaboration across EyeCare Partners sites

This episode exemplifies the spirit of clinical innovation and collaboration that defines our network. We encourage all providers, researchers and team members to tune in and consider how this research may inform future practice.

+++

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

For more information, visit: https://www.abbvie.com/science/areas-of-focus/eye-care.html

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

Hosts Dr. Albert Cheung (Virginia Eye Consultants) and Dr. Sara LeMay (Retina Associates of Kentucky) are joined by retina specialists Dr. Miguel Busquets (Retina Associates of Kentucky) and Dr. Boleslav (Slava) Kotlyar (Vitreous Retina Macula Specialists of New Jersey) explore photobiomodulation (PBM) and the Valeda Light Delivery System, the first FDA-authorized treatment for non-exudative (dry) age-related macular degeneration (AMD). The discussion covers the science behind PBM, using specific wavelengths of light to stimulate mitochondrial function in retinal cells, and its clinical benefits, including improved visual acuity and slowed progression of geographic atrophy.

+++

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

For more information, visit: https://www.abbvie.com/science/areas-of-focus/eye-care.html

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

This episode features a dynamic conversation on two emerging technologies in glaucoma care: Direct Selective Laser Trabeculoplasty (DSLT) and the iDose implant. Hosted by Dr. Katie Rachon and Dr. Constance Okeke, both at Virginia Eye Consultants, this episode includes expert insights from Dr. Anup Khatana of the Cincinnati Eye Institute and Dr. Michael Stiles of Stiles Eyecare Excellence, who discuss clinical applications, patient selection and outcomes. This episode offers valuable guidance for eye care professionals navigating the evolving landscape of interventional glaucoma treatment.

Send us a text

Dr. Belinda Shirkey, vitreoretinal surgeon at Retina Associates of Kentucky, explores the evolving role of Optical Coherence Tomography Angiography (OCTA) in clinical practice. Key topics include: What OCTA is and how it works compared to traditional OCT and fluorescein angiography; its value in diagnosing and managing macular degeneration, diabetic retinopathy and other retinal diseases; practical insights into clinical decision-making and patient selection; and limitations and the future of OCTA in ophthalmology. Whether you’re considering adopting OCTA in your practice or looking for pearls to optimize its use, this episode offers practical and timely insights.

Send us a text

In this episode of the Doc2Doc podcast, hosts Dr. Albert Cheung and Dr. Sara LeMay are joined by Dr. Martin de la Presa, a cornea, cataract and refractive specialist at Grene Vision Group to discuss Fuchs’ corneal dystrophy, its pathophysiology and evolving treatment options.

Dr. de la Presa explains Fuchs is a genetic condition leading to toxic protein accumulation in corneal endothelial cells, resulting in progressive vision loss. He emphasizes the importance of correlating patient symptoms with clinical findings to guide treatment decisions. The conversation explores both medical and surgical treatments. This episode provides practical pearls as well as optimism about future potential treatment options that could make care more accessible and less invasive.

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

In this episode of the Doc2Doc podcast, Derek Jacobsen, O.D., and Lance Stutz, M.D., from Desert Vista Eye Specialists in Arizona discuss Light Adjustable Lens (LAL) technology. They explain how LALs, which allow for post-operative vision fine-tuning using UV light, offer patients a customizable and precise refractive outcome following cataract surgery.

The conversation covers ideal patient candidates, the post-operative journey, co-management between optometrists and ophthalmologists, surgical tips, potential complications and how LALs compare to other premium intraocular lenses. The doctors emphasize the importance of setting patient expectations, managing dry eye and investing in strong collaboration to ensure optimal outcomes. They also share optimism about the future of LAL technology and its potential to become a standard in vision correction.

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

In this episode of the Doc2Doc podcast, Dr. Swarupa Kancherla, Columbus Ophthalmology Associates, and RCM's Sarah Pisano join hosts Dr. Albert Cheung and Dr. Katie Rachon to break down Medicare’s G2211 code, an add-on designed to capture the ongoing care and cognitive work involved in managing chronic or complex conditions. They explore real-world ophthalmology examples where the code applies, offer documentation tips and share how practices can leverage G2211 to better reflect the value of the care providers deliver every day.

+++

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

For more information, visit: https://www.abbvie.com/science/areas-...

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.

Send us a text

In this latest episode of the Doc2Doc podcast, hosts Dr. Sara LeMay, Retina Associates of Kentucky, and Dr. Aparna Shah, Bennett & Bloom Eye Centers, welcome retina specialist Dr. Jeremy Wolfe, Associated Retinal Consultants, to discuss Susvimo, a port delivery system for administering highly concentrated ranibizumab.

Dr. Wolfe explains its design, which allows for slow, sustained drug delivery into the vitreous cavity via simple diffusion. He details the surgical procedure, highlighting its learning curve and support from surgical device specialists, as well as the post-operative follow-up and refill process, which patients in clinical trials strongly preferred over regular intravitreal injections.

Dr. Wolfe also addresses the 2022 voluntary recall due to septum dislocation issues. While the procedure differs from standard retina surgeries, Dr. Wolfe believes it is well within the capabilities of retina specialists, paving the way for broader adoption.

The program is brought to you by our Corporate Sponsor, AbbVie. The opinions of the presenters and the content shared is not created by or necessarily endorsed by AbbVie.

"At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we’re proud to offer 125 eye care products that help to preserve and protect vision for patients around the world. We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases. For more information, visit: https://www.abbvie.com/science/areas-of-focus/eye-care.html."

Copyright ©️ 2025 EyeCare Partners, LLC. All rights reserved.